Manoj Puthenveedu
Manage Your Profile
About
We are interested in how patterns of GPCR signaling are disrupted in highly prevalent and co-morbid diseases - pain/addiction, heart disease, and cancer - and how we can re-engineer and correct these patterns. This is a new idea based on recent exciting data that the same drug/receptor pair can have different effects based simply on the location in the cell from which it signals. We use innovative fluorescence microscopy techniques to directly visualize and study the trafficking and signaling of receptors and effectors in real time. The long-term goal is to identify factors that will allow us to actively relocate receptors to specific sites in the cell, allowing us to change spatial patterns and fine-tune receptor physiology. This is a brand-new and potentially transformative approach to receptor pharmacology and drug development.
Links
Puthenveedu lab
Qualifications
-
Postdoctoral FellowUniversity of California, San Francisco, San Francisco, United States
Postdoctoral Fellowship
-
House SurgeonGovt. Medical College, Calicut, India
Postdoctoral Fellowship
-
PhDCarnegie Mellon University, United States
-
MBBSGovt. Medical College, Calicut, India
Center Memberships
-
Center MemberOpioid Research Institute
Research Overview
- Cell biology of drug addiction
- Alternate non-addictive pain medications
- pH-sensing receptors in cancer immunology
- GPCRs in heart disease
- Innovative fluorescence microscopy and image informatics
Recent Publications
-
Li M, Kochan KE, Stanczyk MA, Stewart HC, West JL, White AD, Weinberg ZY, Puthenveedu MA, Traynor JR. Molecular Pharmacology, 2025 Nov 1; 107 (11):Journal ArticleEffects of two structurally diverse positive allosteric modulators on signaling bias at the μ-opioid receptor
DOI:10.1016/j.molpha.2025.100079 PMID: 41145026 -
Aditya Kumar G, Bagheri Y, Puthenveedu MA. Molecular Biology of the Cell, 2025 Jul 1; 36 (7):Journal ArticleMembrane order regulates clathrin-coated pit dynamics but not initiation
DOI:10.1091/mbc.E25-02-0081 PMID: 40305091 -
Kumar GA, Puthenveedu M. Journal of Pharmacology and Experimental Therapeutics, 2025 Mar 29; 392 (3): 103442Journal ArticleMembrane Order in Clathrin-Mediated Endocytosis of GPCRs (Abstract ID: 191390)
DOI:10.1016/j.jpet.2025.103442 -
Chen H, Kumar GA, Luo Y, Puthenveedu MA. 2025 Jan 1; 2887: Methods in Molecular Biology, 249 - 262.ChapterA Dual-Color Fluorescence-Based Ratiometric Assay to Measure Endocytic Trafficking of Surface Proteins
DOI:10.1007/978-1-0716-4314-3_18 PMID: 39806160 -
Chronis IB, Vistein R, Gokhale A, Faundez V, Puthenveedu MA. Molecular Pharmacology, 2025 Jan 1; 107 (1):Journal ArticleThe β2 adrenergic receptor cross-linked interactome identifies 14-3-3 proteins as regulating the availability of signaling-competent receptors
DOI:10.1124/molpharm.124.000939 PMID: 39919163 -
Chronis IB, Vistein R, Gokhale A, Faundez V, Puthenveedu MA. Mol Pharmacol, 2025 Jan; 107 (1): 100005Journal ArticleThe β2 adrenergic receptor cross-linked interactome identifies 14-3-3 proteins as regulating the availability of signaling-competent receptors.
DOI:10.1124/molpharm.124.000939 PMID: 39919163 -
Chronis I, Puthenveedu MA. Journal of Pharmacology and Experimental Therapeutics, 2024 May 15; 389: 353Proceeding / Abstract / Poster14-3-3 Proteins are Negative Regulators of β2 Adrenergic Receptor Function
DOI:10.1124/jpet.353.950380 -
Momplaisir NL, Delatte M, Puthenveedu MA, Wilkerson J, Edwards E. Trends in Pharmacological Sciences, 2023 Dec 1; 44 (12): 849 - 856.Journal ArticleThriving as members of under-represented groups in pharmacology-related careers
DOI:10.1016/j.tips.2023.08.005 PMID: 37741787
